Sie sind auf Seite 1von 10

In Review

Sleep in Psychiatric Disorders: Where Are We Now?


Elliott Kyung Lee, MD, FRCPC, D ABPN Sleep Medicine, Addiction Psychiatry, D ABSM1,2;
Alan B Douglass, MD, FRCPC, D ABSM1,3

Although the precise function of sleep is unknown, decades of research strongly


implicate that sleep has a vital role in central nervous system (CNS) restoration,
memory consolidation, and affect regulation. Slow-wave sleep (SWS) and rapid
eye movement (REM) sleep have been of significant interest to psychiatrists; SWS
because of its putative role in CNS energy recuperation and cognitive function, and
REM sleep because of its suggested involvement in memory, mood regulation,
and possible emotional adaptation. With the advent of the polysomnogram,
researchers are now beginning to understand some of the consequences of
disrupted sleep and sleep deprivation in psychiatric disorders. The same
neurochemistry that controls the sleep–wake cycle has also been implicated in the
pathophysiology of numerous psychiatric disorders. Thus it is no surprise that
several psychiatric disorders have prominent sleep symptoms. This review will
summarize normal sleep architecture, and then examine sleep abnormalities and
comorbid sleep disorders seen in schizophrenia, as well as anxiety, cognitive, and
substance abuse disorders.
Can J Psychiatry. 2010;55(7):403–412.

Clinical Implications

· REM sleep and SWS may have significant roles in memory consolidation, cognitive
function, affect regulation, and diminishing the emotional valence of memories; these
roles may have significant implications for several psychiatric disorders.
· Sleep is influenced by neurochemistry that is also implicated in the pathophysiology of
numerous psychiatric disorders, which may explain why so many psychiatric disorders
have sleep complaints as a primary symptom; an understanding of these mechanisms
may lead to rational manipulation of these relations and lead to improved clinical care
of numerous psychiatric disorders.
· Psychiatrists should maintain a high index of suspicion for several sleep disorders,
including obstructive sleep apnea, restless legs syndrome, periodic limb movement
disorder, REM behaviour disorder, and even narcolepsy, all of which may be
comorbid or possibly mimic numerous psychiatric disorders, and can even occur as a
consequence of psychiatric care; these disorders may exacerbate underlying
psychiatric symptoms if left untreated.

Limitations

· The precise function of sleep is not known; consequently, efforts to understand and
rationally manipulate sleep are limited.
· There is a paucity of psychiatrists involved in sleep medicine and sleep research; as a
result, an understanding of the role of sleep in psychiatric disorders, and the
psychiatric symptoms of sleep disorders remains limited.

Key Words: sleep, psychiatric disorders, antipsychotic, alcohol, antidepressant,


anxiety, schizophrenia, REM sleep, slow-wave sleep, opioid

The Canadian Journal of Psychiatry, Vol 55, No 7, July 2010 W 403


In Review

S leep is divided into 2 main types: REM sleep and NREM


sleep. NREM sleep is further subdivided; Stages 1 and 2
are light stages of sleep (now referred to as N1 and N2), while
is compromised. PTSD would be a classic example of a mal-
function of this putative emotional adaptation process, where
the emotional content of a previous traumatic event persists.
Stages 3 and 4 are deeper stages (now referred to as N3), col- REM sleep abnormalities are seen in numerous psychiatric
lectively referred to as SWS. SWS is important in CNS energy disorders, some of which will be examined below.
restoration and declarative memory (memory for facts and
[or] events),1,2 which has significant consequences for psychi- Insomnia, defined as difficulty initiating or maintaining sleep
atric disorders with cognitive dysfunction. For example, SWS resulting in daytime consequences, is common among psy-
deficits are seen in schizophrenia3 and Alzheimer disease.4 chiatric disorders. Several potential comorbid sleep disor-
REM sleep likely has a significant role in memory consolida- ders, including OSA, RLS, PLMD, and RBD may modulate
tion and affect regulation. The “mood regulatory function of psychiatric symptom expression. This review will examine
dreaming”5, p 261 hypothesis suggests that the function of the sleep abnormalities and comorbid sleep disorders in schizo-
transition from SWS to REM sleep is to mitigate the affect of phrenia, anxiety, cognitive, and substance abuse disorders.
the previous waking experience.5,6 One model advanced by
Walker7 is that sleep modulates the emotional tone of mem-
ory. In what he called the “sleep to remember” and “sleep to
forget” hypotheses, Walker7 speculates that “emotional mem- Sleep and Schizophrenia
ories” are formed in a “milieu of high adrenergic [emotional] Insomnia in schizophrenia is common, having been objec-
tone.”p 190 Using some elegant experiments, Walker’s data tively validated in 2 large meta-analyses.8,9 Severe insomnia
suggest that while sleep plays a role in enhancing declarative can be a prodromal symptom to psychotic decompensation
memory, sleep (especially REM sleep) may also play a role in and (or) relapse to psychosis following antipsychotic discon-
stripping the emotional valence of a memory over time. For tinuation.10 The sleep abnormality most consistently found in
instance, after an emotionally traumatic event, with multiple patients with schizophrenia is a short REM latency, defined
iterations of sleep, the emotional tone of the memory dimin- as the time from sleep onset to the first REM period.3,11 This
ishes, while the factual memory of the events remains intact. short REM latency is likely secondary to SWS deficits, which
In this hypothesis, several psychiatric disorders may be may passively reduce REM latency.12 SWS deficits have
impacted if this emotional adaptation function of REM sleep been seen frequently in schizophrenia,13 even in first-episode
neuroleptic-naive patients.3 SWS is believed to provide a
cortical restorative recovery from wakefulness1,14 and to
enhance declarative memory consolidation.15 Therefore,
Abbreviations used in this article SWS deficiency in schizophrenia may play a significant role
5-HT serotonin in cognitive and negative symptoms.16 Both short REM
AHI Apnea Hypopnea Index latency17 and SWS deficits18,19 are positively correlated with
CBT cognitive-behavioural therapy
negative symptoms and cognitive dysfunction. Additional
studies illustrate a relation between SWS deficits and CNS
CNS central nervous system
structural abnormalities seen in schizophrenia, including
CPAP continuous positive airway pressure increased ventricular volume.20,21 However, whether this is a
CRF corticotrophin releasing factor cause or an effect of the underlying disorder is unknown.
GAD generalized anxiety disorder
MDD major depressive disorder Shortened REM latency is also seen in narcolepsy and sev-
NREM nonrapid eye movement eral psychiatric disorders,22 limiting the use of this finding. In
severe narcolepsy, the hypnagogic and hypnopompic hallu-
OSA obstructive sleep apnea
cinations, believed to be REM intrusion phenomena of
OSA–HS obstructive sleep apnea–hypopnea syndrome
dreaming into wakefulness, can be misdiagnosed as psy-
PLMD periodic limb movement disorder chotic symptoms of schizophrenia.23,24 This has significant
PLMs periodic limb movements in sleep treatment implications, as stimulant therapy may ameliorate
PTSD posttraumatic stress disorder hypnagogic and hypnopompic hallucinations25 but would
exacerbate schizophrenia. Although challenging, narcoleptic
RBD rapid eye movement behaviour disorder
hallucinations can be distinguished from schizophrenic hal-
REM rapid eye movement
lucinations by their holistic presentation. Narcoleptic hallu-
RLS restless legs syndrome cinations are often characterized by a multimodal perceptual
SNRI serotonin and norepinephrine reuptake inhibitor experience including visual, auditory, and tactile elements,
SSRI selective serotonin reuptake inhibitor whereas in schizophrenia, hallucinations are often unimodal
and frequently auditory.26 Additionally, narcoleptic halluci-
SWS slow-wave sleep
nations are not accompanied by delusional symptoms or loss
TST total sleep time
of touch with reality.26

404 W La Revue canadienne de psychiatrie, vol 55, no 7, juillet 2010


Sleep in Psychiatric Disorders: Where Are We Now?

Table 1 Polysomnographic effects of antipsychotic medicationsa


Decreases
REM Shortens sleep awakenings and
Antipsychotic Tmax, hours t½, hours TST suppression Increases SWS onset latency (or) WASO

Clozapine 3 16 +++ 0 ++ + +++


Quetiapine 1 7 +++ ++ 0 +++ +++
Ziprasidone 5 4–10 +++ +++ +++ + +++
Olanzapine 5 30 +++ 0 +++ + +++
Risperidone 1 3–20 + +++ +++ + ++
Thiothixene 2–4 34 +++ + ++ +++ +++
Haloperidol 4–6 12–36 +++ + ++ +++ +++

0 = no effect; + = mild effect; ++ = moderate effect; +++ = strong effect; Tmax = time to peak plasma concentration; t ½ = half-life;
WASO = wake time after sleep onset
a
Reprinted with permission from Krystal et al30

Antipsychotics and Sleep increase SWS in healthy patients, likely because of less
Antipsychotics are currently the mainstay of schizophrenia 5-HT2 antagonism.30 Paliperidone has not been shown to
treatment.27 First-generation (typical) antipsychotics are pri- increase SWS.38 For a summary of these effects, see Table 1.
marily dopaminergic antagonists, with antihistaminergic and Interpreting these findings can be challenging because these
anticholinergic effects. Second-generation (atypical) effects are studied in different populations, from control sub-
antipsychotics have the added effect of blocking serotonergic jects to patients with different psychiatric conditions, leading
receptors and are associated with improvement of negative to conflicting findings. Additionally, it is unclear that simply
and cognitive symptoms.28 The central H1 (histaminergic reversing the SWS abnormalities results in clinical improve-
one) antihistaminergic effects of antipsychotics have signifi- ment of schizophrenia symptoms. However, there is clinical
cant sedating properties, which may be beneficial for patients utility in understanding sleep architecture changes that occur
with schizophrenia and insomnia. Olanzapine is the most with antipsychotics. For instance, quetiapine is an appropri-
sedating of the atypical antipsychotics.29 However, excessive ate choice for sleep-onset insomnia, as it reaches peak blood
daytime sedation can facilitate a reversal of the sleep–wake levels quickly, has a relatively short half-life compared with
cycle, as daytime naps may enhance nighttime wakefulness, the other atypical antipsychotics, and significantly shortens
p a r a d o x i c a l l y e x a c e r b a t i n g in s o mn i a . 3 0 A n o th e r sleep latency. Other atypical antipsychotics including
antihistaminergic effect is increased appetite and weight gain, olanzapine, risperidone, or clozapine may take up to 1 week
which can increase the risk of developing OSA.31 OSA may for blood levels to peak. 30 Conversely, ziprasidone,
often go unrecognized in these patients and can contribute to olanzapine, or risperidone may be more suitable for sleep
several problems including aggressive behaviours. Anecdotal maintenance insomnia, owing to their relatively powerful
reports of severely aggressive patients with schizophrenia and potential to increase SWS; however, daytime sedation can be
unrecognized OSA have shown that, once treated with CPAP, a side effect.30
aggressive tendencies diminished dramatically.32
Sleep in Anxiety Disorders
Dopaminergic antagonism also has significant sleep effects.
Dopamine antagonism has been linked to exacerbation of Patients with anxiety disorders, including GAD, PTSD, and
RLS and PLMs, which can fragment sleep and contribute to panic disorder, often have disturbed sleep. Insomnia is the
daytime sleepiness. This has been demonstrated in case most common sleep complaint in these disorders. A large
reports for olanzapine,33 risperidone,34 and quetiapine.35 cross-sectional study by Ohayon and Roth39 showed 61% of
panic disorder patients and 44% of patients with GAD had
Serotonergic actions also play a role in sleep architecture insomnia. Insomnia can have several etiologies, including
changes. 5-HT1A agonist effects suppress REM sleep.30 For RLS, or an underlying common neurochemical abnormality.
instance, ziprasidone has strong 5-HT1A agonism effects and
significantly suppresses REM sleep.30 Increased SWS is cor- RLS and Anxiety Disorders
related significantly with 5-HT2 antagonism. Olanzapine36 RLS is often described as a creepy-crawly or tingling sensa-
and risperidone37 have high 5-HT2 antagonism and are tion in the lower limbs associated with a strong desire to
reported to increase SWS the most among antipsychotics. move, usually worsened by rest and worse in the evenings.40
Ziprasidone also increases SWS, but quetiapine does not Because symptoms frequently occur in late evening, they

The Canadian Journal of Psychiatry, Vol 55, No 7, July 2010 W 405


In Review

often cause initial insomnia. RLS is strongly related to PLMD, patients with nocturnal panic attacks have reduced heart rate
in which the legs move periodically in the night, usually at 20- variability and a “qualitatively different cardio-
to 40-second intervals, causing fragmented sleep and middle physiology,”55, p 461 possibly suggesting that these patients
insomnia. CNS dopamine deficiency is strongly implicated in have a distinct variant of panic disorder. Evaluation should
RLS and PLMD.41 RLS prevalence estimates indicate 5% to consist of a sleep evaluation to screen for other diagnoses
10% of the population may be affected.42 Several recent stud- such as night terrors, sleep paralysis, seizures, PLMD, and, in
ies highlight a strong preponderance of anxiety disorders in particular, OSA, as apneic events can trigger nocturnal panic
RLS patients, especially panic disorder.43 The relation may lie attacks.54
in a common dopaminergic abnormality.43 Antidepressant use
is also linked to RLS, including the tricyclics and SSRIs,44 PTSD and Sleep
venlafaxine,45 and, particularly, mirtazapine.44 Recent studies Studies evaluating sleep in PTSD have shown frequent
suggest an average 5% to 10% increase in incidence of RLS arousals, fragmented sleep, and increased motor activity.57
symptoms with SSRI or SNRI antidepressant use, but up to a Although reports on sleep architecture changes are inconsis-
30% increase with mirtazapine and no increase with tent, a large recent meta-analysis showed PTSD patients have
reboxetine use.44 Although SSRIs and SNRIs may exacerbate more Stage 1 sleep, less SWS, and higher REM density.58
RLS, bupropion has been suggested to be neutral for RLS The losses in SWS may be mediated by increases in
symptoms and possibly even helpful for RLS because of its cerebrospinal fluid CRF, which is known to inhibit SWS.59
dopaminergic activity.46 As untreated RLS is associated with CRF dysregulation may be a core feature of PTSD; as a
insomnia47 and poor quality of life,48 it behooves psychiatrists result, CRF receptor antagonists are being developed as ther-
to recognize this disorder. Many patients with anxiety disor- apeutic targets for treatment of PTSD symptoms.59,60
ders may have unrecognized RLS. If RLS symptoms occur REM sleep abnormalities in PTSD have attracted significant
more than 3 times per week, treatment with a dopamine ago- attention. Several studies show higher REM density and
nist such as pramipexole or ropinirole 2 hours before bed- increased REM latency61 in these patients. Multiple lines of
time49 can be beneficial. evidence suggest REM sleep continuity is disrupted in
chronic PTSD. 62,63 Some studies have demonstrated
GAD and Sleep increased muscle tone in REM sleep, further suggesting a
GAD is commonly associated with insomnia. Although GAD dysfunction of REM sleep mechanisms, as REM sleep nor-
has a high comorbidity with MDD, polysomnography studies mally has skeletal muscle atonia.57,64 PLMs also occur fre-
of these patients do not consistently demonstrate the reduction quently in PTSD.57 Dream enactment behaviour has also
in REM latency seen in MDD.50 These studies also showed been evaluated in patients with PTSD,64,65 though surpris-
that GAD patients have less SWS and more awakenings than ingly few studies have evaluated this comorbidity, given how
control subjects.51 Daytime vigilance and attention remain often parasomnia behaviours occur, including yelling, shout-
stable despite SWS deprivation and fragmented sleep, but fine ing, and kicking.
motor control and reaction time are diminished, suggesting
some deficits from sleep disturbances.52 Benca et al8 per- Nightmares and PTSD
formed a large review of sleep findings in patients with GAD Nightmares occur in up to 96% of PTSD patients,66 predomi-
and concluded that while studies consistently reported an nantly emerging from REM sleep.63 Mellman51 has observed
increased sleep latency and decreased sleep efficiency in these that in patients exposed to trauma, those who develop PTSD
patients, findings in SWS, REM latency, REM density, and describe dream content that is “highly replicative”p 1052 of the
REM quantity were variable. trauma; whereas those who do not develop PTSD describe
dreams with a significant fear component but that are not
Panic Disorder and Sleep replicative of the traumatic events. Mellman theorizes that
Several surveys show an association between insomnia and these replicative dreams in PTSD represent a “failure of
panic disorder, with up to 68% of patients with panic disorder adaptive emotional memory that is a normal functioning of
identifying problems falling asleep and 77% of patients with REM sleep and dreaming.”51, p 1052 This theory is consistent
panic disorder endorsing difficulties maintaining adequate with Walker’s “sleep to forget hypothesis”7, p 190 (discussed
sleep.50 Panic attacks evolving from sleep (sleep panic attacks earlier), as PTSD is envisioned as a failure of the normal
or nocturnal panic attacks) may result in insomnia because function of REM sleep to remove the emotional content of a
sleep may become regarded as a fearful panicogenic state.53 memory, leading some to speculate that PTSD symptoms
Between 44% and 71% of patients with panic disorder experi- may represent a form of sleep disorder,67 in contrast to the tra-
ence sleep panic attacks,54 with 18% to 45% of panic attacks ditional view that sleep disturbances are a symptom of PTSD.
arising from sleep.50,55 Sleep evaluations have established that Several nonpharmacologic measures have been shown to be
nocturnal panic attacks typically occur at the transition beneficial for nightmares, including imagery rehearsal ther-
between Stages 2 and 3 of sleep56 and are distinct from night apy and CBT, either alone or in combination.68 Eye move-
terrors and other parasomnias, as well as from panic attacks ment desensitization and reprocessing may also help with
occurring after nocturnal awakening. Recent studies show sleep efficiency in PTSD.69 Another nonpharmacologic

406 W La Revue canadienne de psychiatrie, vol 55, no 7, juillet 2010


Sleep in Psychiatric Disorders: Where Are We Now?

intervention for PTSD is CPAP. Some studies have demon- include depression,92 cognitive dysfunction,93 poorer quality
strated frequencies of OSA in PTSD patients of more than of life, and increased mortality.94 Prevalence estimates of
90%,70 while another study of community patients with PTSD sleep complaints in the elderly approach 30% to 50%,95 mak-
showed no increase in OSA.62 Treatment of underlying OSA ing sleep important to address in this population.
in PTSD patients may significantly improve nightmares and
insomnia symptoms.71 Patients with PTSD and OSA may not Insomnia in the Elderly
report the typical sleepiness reported by classic OSA patients, Insomnia is the most common sleep difficulty reported in
as this may be masked by heightened anxiety; instead, they elderly adults, especially elderly women.96 The prevalence of
may report fatigue or tiredness. Krakow et al72 demonstrated insomnia increases sharply with the number of medical and
that these patients report nocturia, morning headaches, and psychiatric conditions present, the most common being
dry mouth, which may be better indicators of comorbid OSA depression, chronic pain, cancer, chronic obstructive pulmo-
in this population. For excellent reviews of sleep abnormali- nary disease, and cardiovascular disease. In an extensive
ties in PTSD, see Spoormaker and Montgomery67 and review of 6800 elderly patients with insomnia, only 7% of
Germain et al.73 those with incident insomnia did not have one of these condi-
tions, leading the authors to conclude that medical conditions
The heightened arousal and disturbing dreams in PTSD likely
associated with aging lead to insomnia, rather than aging
originate from an overactive noradrenergic system, with
itself.97 Many medications also have insomnia as a side
involvement of the limbic system including the amygdala and
effect.
medial prefrontal cortex.73 Prazosin, an alpha-1 adrenergic
antagonist, has significant nightmare attenuation properties. Circadian Rhythm Disturbances in the Elderly
This agent diminishes noradrenergic activity of the locus
The sleep–wake cycle is controlled by the suprachiasmatic
coeruleus, thereby decreasing nightmare frequency and inten-
nucleus, located in the anterior hypothalamus. Together with
sity.74,75 Studies used between 1 and 20 mg/day, with a mean
external time cues (zeitgebers), particularly exogenous light
effective dosage of 2 to 13 mg/day.75 The 5-HT2A receptors
and endogenous melatonin, the suprachiasmatic nucleus
also play an important role in nightmare experiences and sleep
entrains the body’s circadian rhythms, including the
disturbances in PTSD. Other medications that have demon-
sleep–wake cycle. This system becomes less robust with age,
strated efficacy for sleep in PTSD include 5-HT2 antagonists,
and more prone to phase advancing. Therefore, the elderly
many with antiadrenergic activity, including trazodone,76
may have a tendency to retire early and arise early. Conse-
mirtazapine,77 olanzapine,78 risperidone,79 quetiapine,80
quently, 2 patterns may emerge that exacerbate insomnia.98
aripiprazole,81 as well as the anticonvulsants topiramate82 and
Some elderly may stay awake longer, to more socially
gabapentin.83 The latter 2 agents may reduce kindling–
accepted norms but then wake up early in the morning unable
hyperreactivity of the limbic system. Other recently studied
to return to sleep because their bodily rhythm is entrained to
medications with demonstrated sleep benefits in PTSD
an early morning rising. Alternatively, the elderly can feel
include nabilone84 and dehydroepiandrosterone-sulphate.85
more fatigued earlier in the day and take daytime naps, caus-
For further details regarding use of these medications, and
ing initial and middle insomnia because of less nocturnal
anecdotal reports of other medications with some demon-
sleep debt.
strated benefits in sleep parameters for patients with PTSD,
see the review by Berger et al.86 Among the SSRIs, only Sleep Disorders in the Elderly
fluvoxamine87 has demonstrated improvement in sleep
Obstructive Sleep Apnea–Hypopnea Syndrome. OSA is
parameters, although SSRIs are still first-line medications for
characterized by repeated pharyngeal obstructions resulting
other PTSD symptoms.86 While benzodiazepines are fre-
in airflow cessation (apnea) or reduction (hypopnea) during
quently used, there is sparse literature on their efficacy for
sleep; these lead to sleep deprivation, fragmentation, and
sleep in PTSD, with only temazepam demonstrating improve-
hypoxemia. The AHI and Respiratory Disturbance Index
ments.88 Although this paucity of literature has led several
(commonly referred to by its acronym, RDI) are 2 measures
investigators to argue against benzodiazepine use in this pop-
used to quantify OSA severity. These indices measure the
ulation,75,86 one exception may be when a parasomnia is
frequencies of sleep-disordered breathing events per hour of
observed, as clonazepam is highly effective for parasomnias
sleep, with higher values indicating more severe distur-
such as sleepwalking89 and RBD.89
bances. CPAP is usually the optimal treatment for OSA, but
surgery (uvulopalatopharyngoplasty) or an oral appliance
Sleep and Cognitive Disorders can be considered for milder cases, although these are used
Normal Sleep Changes in the Elderly infrequently in OSA in the elderly.
Aging is associated with several changes in sleep architecture. Among adults aged 30 to 60 years, the prevalence of OSA,
Large studies indicate that percentages of REM sleep and defined as an AHI of greater than 5, is 9% for women and
SWS decrease with age.90 However, there is consensus that 24% for men.99 The prevalence of OSA–HS, defined as an
the need for sleep does not change with aging, but the ability to AHI of greater than 5 and daytime hypersomnolence, is 2%
sleep diminishes.91 The consequences of poor-quality sleep for women and 4% for men.99 For people aged 61 years and

The Canadian Journal of Psychiatry, Vol 55, No 7, July 2010 W 407


In Review

older, prevalence rates of OSA may rise sharply. The Sleep These agents may be problematic for patients with psychotic
Heart Health Study,100 one of the largest studies evaluating symptoms and (or) impulse control difficulties, including
OSA in the elderly, showed stable prevalence rates across age pathological gambling and hypersexuality.109 Another option
groups from 60 to 98 years, with 51% to 66% having an AHI is gabapentin.49 Benzodiazepines and opioids are considered
of more than 5. Several medical conditions predispose the third- and fourth-line options. 49
elderly to developing OSA, including stroke, diabetes (with
autonomic neuropathy possibly altering ventilatory control
mechanisms), renal failure (possibly owing to excess fluid RBD in the Elderly
accumulation), hypothyroidism, obesity, and heart disease. In RBD, the normal skeletal muscle atonia of REM sleep is
However, other studies show an increased risk of OSA in geri- intermittently absent, resulting in complex motor behaviours
atric patients in the absence of these conditions (reviewed by during REM sleep; dream content is then enacted, often
Norman and Loredo101). Multiple mechanisms have been sug- involving themes of aggression or self-defence. Almost 90%
gested to explain this increased vulnerability to developing of affected patients are male, often presenting in their 60s.110
OSA, including decreased pharyngeal dilator activity, and These patients are at high risk for developing alpha
excess pharyngeal fat deposits (reviewed by Norman and synucleinopathies, including Parkinson disease, Lewy Body
Loredo101). Additionally, postmenopausal women not on hor- Dementia, and Multisystem Atrophy.111 Recent research sug-
mone replacement therapy may lose the protective effect of gests RBD patients have a 20% risk of developing Parkinson
estrogen on the upper airway.101 Further, patients with disease or dementia within 5 years, and a 40% risk in 10
dementias may have progressive deterioration of brain stem years,112,113 suggesting RBD is an early clinical marker of
structures involved in maintaining airway patency and conse- these disorders. Several case reports have identified medica-
quently are at higher risk of developing OSA. 102 tions that exacerbate RBD, including tricyclic antidepres-
sants, 64 monoamine oxidase inhibitors, 114 SSRIs, 115
Although snoring and daytime sleepiness are common OSA
mirtazapine, 116 and venlafaxine. 115 RBD responds to
symptoms in elderly patients, other symptoms include insom-
clonazepam (0.5 to 2.0 mg at bedtime) in 80% of patients.117
nia, nocturia, irritability, morning headaches, depression, and
However, clonazepam can increase fall risk and worsen
cognitive impairment.101 Clinicians may overlook these clues,
OSA; in these patients, melatonin may be beneficial.118
ascribing these symptoms to aging or medical issues.103
Patients with more severe OSA perform worse on dementia
rating scales, suggesting a correlation between dementia and Sleep in Dementia
OSA severity.104 Other studies highlight the strong associa-
tion between OSA and increased risk of cardiovascular dis- Sleep is frequently disturbed in patients with dementia.
ease including heart disease, and hypertension in the elderly Often, they are institutionalized and consequently have little
population.101,105 ambient light exposure. They may also have high exposure to
nocturnal noise and medications affecting sleep. 119
As there are significant consequences for OSA in the geriatric Suprachiasmatic nucleus neurons may degenerate more
population, the psychiatrist should maintain a high index of quickly in patients with progressive dementias.120 Melatonin,
suspicion, as OSA is common and often undiagnosed. Refer- a hormone normally produced by the pineal gland to regulate
ral should be considered if there are symptoms suggestive of sleep cycles, has been shown to be diminished by up to 80%
OSA with comorbid nocturia, cardiovascular disease, hyper- in elderly patients with dementia.121 Investigators have
tension, or cognitive dysfunction.106 CPAP is the treatment of examined melatonin use for insomnia in dementia patients,
choice, and has been shown to improve cognitive with benefit in some,122 but not all studies.123 A synthetic
functioning.104 Although CPAP compliance may be challeng- melatonin receptor agonist, ramelteon, has been developed
ing, contrary to what clinicians may believe, patients with and approved for treatment of insomnia in the United
dementia can adapt to CPAP use with proper assistance. A States.124 For a review on other medications used for insom-
study by Ayalon et al107 showed that neither age, severity of nia in the elderly population, see Bloom et al.124
dementia, nor severity of OSA correlated with poor CPAP
adherence; only comorbid depression predicted poorer Additionally, the elderly may have insomnia related to pain,
compliance. medications, depression, or a primary sleep disorder such as
OSA, RLS, PLMD, or RBD. Treatment should begin by
RLS and PLMD in the Elderly addressing all the aforementioned disorders. Several studies
The prevalence of RLS and PLMD rises sharply with age,108 demonstrated that increasing bright light exposure, minimiz-
with women twice as likely to be affected as men. RLS exacer- ing ambient noise, and addressing sleep hygiene are effective
bates initial insomnia, as symptoms usually occur before sleep at improving sleep quality and consolidating the sleep–wake
onset. PLMD may exacerbate middle insomnia because noc- cycle.125,126 CBT, which includes a combination of sleep
turnal leg movements can fragment sleep. Both respond to hygiene, relaxation techniques, stimulus control, and sleep
dopaminergic therapy, including ropinirole or pramipexole, restriction, was more effective at maintaining improvements
considered first-line pharmacologic recommendations.49 in insomnia than temazepam at 2-year follow-up.127

408 W La Revue canadienne de psychiatrie, vol 55, no 7, juillet 2010


Sleep in Psychiatric Disorders: Where Are We Now?

Substance Use and Sleep irritability,140 which may be connected to REM and (or) SWS
deficits. REM sleep deprivation may be hyperalgesic,142
Alcohol and Sleep
leading to speculation that opioids paradoxically reduce the
Acute alcohol use results in decreased sleep latency, modest
pain threshold by reducing REM sleep, possibly resulting in a
increases in SWS, and a reduction of REM sleep in the first 2
vicious cycle of excess opioid requirements.143 However,
to 4 hours of the night.128 These properties make alcohol an
pain itself also reduces REM and NREM sleep, and disrupts
appealing hypnotic; up to 67% of insomniacs report alcohol as
sleep continuity, thereby making this a complex relation
an effective hypnotic.129 However, during the second half of
requiring further study.
the night, REM sleep rebounds and is associated with intense
dreaming and nightmares, leading to sleep fragmentation and Several sleep complications occur with chronic opioid use,
decreased sleep efficiency.128 These disruptive effects can especially methadone. Chronic opioid use is associated with
even be seen 6 hours after happy hour drinking (about 5 PM); the development of central sleep apnea occurring as a conse-
that is, when blood alcohol levels are zero.130 quence of chronic suppression of ventilatory drive. This
However, the effects of chronic alcohol use are quite different dose-dependent phenomenon has been seen in 30% of
from acute use. Tolerance to alcohol’s sleep-enhancing patients on stable methadone maintenance.144 An increase in
effects develops within 3 to 9 nights of daily alcohol use.130 OSA has also been observed in 39% of patients receiving
Chronic use leads to increased sleep latency and decreased chronic opioid therapy145; these phenomena may play a role
sleep efficiency, SWS, REM sleep, and TST.128 These distur- in the sleep disturbances and increased mortality seen in
bances can persist months after alcohol cessation, even up to 2 these patients.146
years, although gradual improvement is generally noted.130,131
Sleep disturbances persisting in early recovery from alcohol Cannabinoids and Sleep
dependence are associated with higher relapse risk.132,133 Studies on the main active ingredient of marijuana, delta-9
Benzodiazepines for the treatment of insomnia are avoided tetrahydrocannabinol, show decreases in sleep latency,147,148
because of their abuse potential in abstinent alcoholics. Very making marijuana potentially appealing as a sedative. Both
little work has been done on evaluating other related pharma- increases and decreases in SWS have been seen with mari-
cologic agents for insomnia in these patients, such as juana use.149 Tolerance to sleep-induction effects of mari-
zopiclone, zolpidem, or zaleplon, because of similar con- juana has been demonstrated in studies of chronic marijuana
cerns. Medications shown to improve sleep disturbances in users.149 Marijuana’s sleep effects can be variable149 because
this population include trazodone,134 carbamazepine,135 it contains numerous compounds, some with sedative effects
acamprosate,136 and gabapentin.137 and others with wakefulness-promoting properties such as
cannabidiol.147,148 Marijuana also decreases REM sleep and
Alcohol use may exacerbate several sleep disorders, includ- REM density.149 These findings have led investigators to use
ing OSA, PLMD, and RLS, as well as parasomnias such as nabilone, a synthetic cannabinoid, for mitigating PTSD
sleepwalking and RBD. OSA and snoring are worsened by nightmares with some reported success.84 Cannabis with-
alcohol, even after a single drink.130 PLMD and RLS preva- drawal has been associated with sleep disturbances, with dis-
lence increases 2- to 3-fold in patients having 2 or more drinks turbing dreams most consistently reported.150 Withdrawal
per day. 130 The exacerbation of parasomnias, such as symptoms begin 2 to 3 days after the last cannabis use and
sleepwalking, may also have distinct forensic implications,128 generally last up to 2 weeks, although they can persist up to
including “sexsomnia,” 138, p 272 a potentially violent 7 weeks.149 Sleep onset latency increases, with reduced SWS
parasomnia where sexual behaviours are enacted in sleep.138 and increased REM sleep,149 consistent with the disturbing
dreams reported by patients.150
Opiates and Sleep
Most studies of opioid effects on sleep have examined heroin,
morphine, and methadone. Acute opioid administration Summary
causes reductions in TST, REM sleep, and SWS.139 With Sleep and sleep disorders are intimately tied to psychiatric ill-
chronic opioid use, these changes are minimized. In opioid ness. This is true at both the clinical–behavioural and the
withdrawal, insomnia frequently occurs, with reduced SWS neurochemical levels. Most psychiatric medications target
and markedly diminished REM sleep.140 Maximal REM and receptors involved in the control of sleep. Additionally, it
SWS suppression occurs 2 to 3 days into abstinence for appears that physical sleep disorders are pathoplastic to psy-
chronic heroin users, and some suppression persists for 5 to 7 chiatric disorders, and need to be suspected by every practis-
days into abstinence.141 With protracted abstinence, TST, ing psychiatrist when evaluating the sleep complaints of their
REM sleep, and SWS subsequently increase (rebound). The parents. Future research may change the way psychiatric dis-
time course for changes in sleep architecture have not been orders are viewed, with a growing understanding of the
studied for each opioid; however, for methadone, REM and bidirectional relation between sleep disturbances and psychi-
SWS rebound occurs 13 to 22 weeks after methadone with- atric symptoms. There is an opportunity to develop new treat-
drawal.139 These sleep changes may explain some behavioural ment strategies for psychiatric disorders based on a broader
changes seen during this withdrawal phase, including initial understanding of sleep physiology and pathophysiology.

The Canadian Journal of Psychiatry, Vol 55, No 7, July 2010 W 409


In Review

31. Partinen M, Telakivi T. Epidemiology of obstructive sleep apnea syndrome.


Acknowledgements Sleep. 1992;15:S1–S4.
The Canadian Psychiatric Association proudly supports the 32. Dennis JL, Crisham KP. Chronic assaultive behavior improved with sleep
apnea treatment. J Clin Psychiatry. 2001;62:571–572.
In Review series by providing an honorarium to the authors. 33. Kraus T, Schuld A, Pollmacher T. Periodic leg movements in sleep and restless
legs syndrome probably caused by olanzapine. J Clin Psychopharmacol.
1999;19:478–479.
References 34. Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by
risperidone treatment. Pharmacopsychiatry. 2002;35:109–111.
1. Horne J. Human slow wave sleep: a review and appraisal of recent findings, with 35. Urbano MR, Ware JC. Restless legs syndrome caused by quetiapine
implications for sleep functions, and psychiatric illness. Experientia. successfully treated with ropinirole in 2 patients with bipolar disorder. J Clin
1992;48:941–954. Psychopharmacol. 2008;28:704–705.
2. Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev. 36. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, et al. Low delta sleep
2006;10:49– 62. predicted a good clinical response to olanzapine administration in schizophrenic
3. Poulin J, Daoust AM, Forest G, et al. Sleep architecture and its clinical correlates patients. Rev Invest Clin. 2004;56:345–350.
in first episode and neuroleptic-naive patients with schizophrenia. Schizophr 37. Yamashita H, Morinobu S, Yamawaki S, et al. Effect of risperidone on sleep in
Res. 2003;62:147–153. schizophrenia: a comparison with haloperidol. Psychiatry Res.
4. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep 2002;109:137–142.
Med. 2007;8 Suppl 4:S27–S34. 38. Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled,
5. Cartwright R, Agargun MY, Kirkby J, et al. Relation of dreams to waking randomized study evaluating the effect of paliperidone extended-release tablets
concerns. Psychiatry Res. 2006;141:261–270. on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol.
6. Moffit A, Kramer M, Hoffman R, editors. The selective mood regulatory 2007;22:299–308.
function of dreaming: an upate and revision. New York (NY): State University of 39. Ohayon MM, Roth T. What are the contributing factors for insomnia in the
New York Press; 1993. general population? J Psychosom Res. 2001;51:745–755.
7. Walker MP. The role of sleep in cognition and emotion. Ann N Y Acad Sci. 40. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic
2009;1156:168 –197. criteria, special considerations, and epidemiology. A report from the restless
8. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders. legs syndrome diagnosis and epidemiology workshop at the National Institutes
A meta-analysis. Arch Gen Psychiatry. 1992;49:651– 668; discussion 669– 670. of Health. Sleep Med. 2003;4:101–119.
9. Chouinard S, Poulin J, Stip E, et al. Sleep in untreated patients with 41. Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic
schizophrenia: a meta-analysis. Schizophr Bull. 2004;30:957–967. treatment of restless legs syndrome and periodic limb movement disorder.
10. Dencker SJ, Malm U, Lepp M. Schizophrenic relapse after drug withdrawal is Sleep. 2004;27:560–583.
predictable. Acta Psychiatr Scand. 1986;73:181–185. 42. Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in
11. Zarcone VP Jr, Benson KL, Berger PA. Abnormal rapid eye movement latencies adults. Arch Intern Med. 2000;160:2137–2141.
in schizophrenia. Arch Gen Psychiatry. 1987;44:45–48. 43. Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with
12. Benson KL. Sleep in schizophrenia: impairments, correlates, and treatment. DSM-IV major depressive disorder and panic disorder in the community.
Psychiatr Clin North Am. 2006;29:1033–1045; abstract ix–x. J Neuropsychiatry Clin Neurosci. 2008;20:101–105.
13. Keshavan MS, Reynolds CF 3rd, Miewald MJ, et al. Delta sleep deficits in 44. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side
schizophrenia: evidence from automated analyses of sleep data. Arch Gen effect of second generation antidepressants. J Psychiatr Res. 2008;43:70–75.
Psychiatry. 1998;55:443–448. 45. Yang C, White DP, Winkelman JW. Antidepressants and periodic leg
14. Benington JH, Heller HC. Restoration of brain energy metabolism as the movements of sleep. Biol Psychiatry. 2005;58:510–514.
function of sleep. Prog Neurobiol. 1995;45:347–360. 46. Lee JJ, Erdos J, Wilkosz MF, et al. Bupropion as a possible treatment option for
15. Marshall L, Helgadottir H, Molle M, et al. Boosting slow oscillations during restless legs syndrome. Ann Pharmacother. 2009;43:370–374.
sleep potentiates memory. Nature. 2006;444:610–613. 47. Ulfberg J, Nystrom B, Carter N, et al. Prevalence of restless legs syndrome
16. Keshavan MS, Miewald J, Haas G, et al. Slow-wave sleep and symptomatology among men aged 18 to 64 years: an association with somatic disease and
in schizophrenia and related psychotic disorders. J Psychiatr Res. neuropsychiatric symptoms. Mov Disord. 2001;16:1159–1163.
1995;29:303–314. 48. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of
17. Tandon R, Shipley JE, Taylor S, et al. Electroencephalographic sleep RLS in an elderly population: the MEMO study. Memory and Morbidity in
abnormalities in schizophrenia. Relationship to positive/negative symptoms and Augsburg Elderly. Neurology. 2000;54:1064–1068.
prior neuroleptic treatment. Arch Gen Psychiatry. 1992;49:185–194. 49. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of
18. Ganguli R, Reynolds CF 3rd, Kupfer DJ. Electroencephalographic sleep in restless legs syndrome. Mayo Clin Proc. 2004;79:916–922.
young, never-medicated schizophrenics. A comparison with delusional and
50. Papadimitriou GN, Linkowski P. Sleep disturbance in anxiety disorders. Int
nondelusional depressives and with healthy controls. Arch Gen Psychiatry.
Rev Psychiatry. 2005;17:229–236.
1987;44:36–44.
51. Mellman TA. Sleep and anxiety disorders. Psychiatr Clin North Am.
19. Kato M, Kajimura N, Okuma T, et al. Association between delta waves during
2006;29:1047–1058; abstract x.
sleep and negative symptoms in schizophrenia. Pharmaco-eeg studies by using
52. Saletu-Zyhlarz G, Saletu B, Anderer P, et al. Nonorganic insomnia in
structurally different hypnotics. Neuropsychobiology. 1999;39:165–172.
generalized anxiety disorder. 1. Controlled studies on sleep, awakening and
20. Benson KL, Sullivan EV, Lim KO, et al. Slow wave sleep and computed
daytime vigilance utilizing polysomnography and EEG mapping.
tomographic measures of brain morphology in schizophrenia. Psychiatry Res.
Neuropsychobiology. 1997;36:117–129.
1996;60:125–134.
21. van Kammen DP, van Kammen WB, Peters J, et al. Decreased slow-wave sleep 53. Craske MG, Lang AJ, Tsao JC, et al. Reactivity to interoceptive cues in
and enlarged lateral ventricles in schizophrenia. Neuropsychopharmacology. nocturnal panic. J Behav Ther Exp Psychiatry. 2001;32:173–190.
1988;1:265–271. 54. Craske MG, Tsao JC. Assessment and treatment of nocturnal panic attacks.
22. Aldrich MS. Diagnostic aspects of narcolepsy. Neurology. 1998;50:S2–S7. Sleep Med Rev. 2005;9:173–184.
23. Kishi Y, Konishi S, Koizumi S, et al. Schizophrenia and narcolepsy: a review 55. Aikins DE, Craske MG. Sleep-based heart period variability in panic disorder
with a case report. Psychiatry Clin Neurosci. 2004;58:117–124. with and without nocturnal panic attacks. J Anxiety Disord. 2008;22:453–463.
24. Douglass AB, Shipley JE, Haines RF, et al Schizophrenia, narcolepsy, and 56. Mellman TA, Uhde TW. Electroencephalographic sleep in panic disorder.
HLA-DR15, DQ6. Biol Psychiatry. 1993;34:773–780. A focus on sleep-related panic attacks. Arch Gen Psychiatry. 1989;46:178–184.
25. Douglass AB. Narcolepsy: differential diagnosis or etiology in some cases of 57. Germain A, Nielsen TA. Sleep pathophysiology in posttraumatic stress disorder
bipolar disorder and schizophrenia? CNS Spectr. 2003;8:120–126. and idiopathic nightmare sufferers. Biol Psychiatry. 2003;54:1092–1098.
26. Fortuyn HA, Lappenschaar GA, Nienhuis FJ, et al. Psychotic symptoms in 58. Kobayashi I, Boarts JM, Delahanty DL. Polysomnographically measured sleep
narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp abnormalities in PTSD: a meta-analytic review. Psychophysiology.
Psychiatry. 2009;31:146–154. 2007;44:660–669.
27. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of 59. Neylan TC, Otte C, Yehuda R, et al. Neuroendocrine regulation of sleep
schizophrenia. Can J Psychiatry. 2005;50(13 Suppl 1):7S–57S. disturbances in PTSD. Ann N Y Acad Sci. 2006;1071:203–215.
28. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical 60. Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety
needs in the treatment of schizophrenia: a review of the new generation disorders: a translational research perspective. Horm Behav. 2006;50:550–561.
antipsychotics. Int Clin Psychopharmacol. 2005;20:183–198. 61. Mellman TA, David D, Kulick-Bell R, et al. Sleep disturbance and its
29. Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of relationship to psychiatric morbidity after Hurricane Andrew. Am J Psychiatry.
antipsychotics in patients with bipolar disorder or schizophrenia: focus on 1995;152:1659–1663.
somnolence. J Clin Psychiatry. 2008;69:302–309. 62. Breslau N, Roth T, Burduvali E, et al. Sleep in lifetime posttraumatic stress
30. Krystal AD, Goforth HW, Roth T. Effects of antipsychotic medications on sleep disorder: a community-based polysomnographic study. Arch Gen Psychiatry.
in schizophrenia. Int Clin Psychopharmacol. 2008;23:150–160. 2004;61:508–516.

410 W La Revue canadienne de psychiatrie, vol 55, no 7, juillet 2010


Sleep in Psychiatric Disorders: Where Are We Now?

63. Mellman TA, Kulick-Bell R, Ashlock LE, et al. Sleep events among veterans 94. Dew MA, Hoch CC, Buysse DJ, et al. Healthy older adults’ sleep predicts
with combat-related posttraumatic stress disorder. Am J Psychiatry. all-cause mortality at 4 to 19 years of follow-up. Psychosom Med.
1995;152:110–115. 2003;65:63–73.
64. Husain AM, Miller PP, Carwile ST. REM sleep behavior disorder: potential 95. Ohayon MM. Epidemiology of insomnia: what we know and what we still need
relationship to post-traumatic stress disorder. J Clin Neurophysiol. to learn. Sleep Med Rev. 2002;6:97–111.
2001;18:148–157. 96. Rediehs MH, Reis JS, Creason NS. Sleep in old age: focus on gender
65. Ross RJ, Ball WA, Dinges DF, et al. Motor dysfunction during sleep in differences. Sleep. 1990;13:410–424.
posttraumatic stress disorder. Sleep. 1994;17:723–732. 97. Foley DJ, Monjan A, Simonsick EM, et al. Incidence and remission of insomnia
66. Leskin GA, Woodward SH, Young HE, et al. Effects of comorbid diagnoses on among elderly adults: an epidemiologic study of 6,800 persons over three years.
sleep disturbance in PTSD. J Psychiatr Res. 2002;36:449–452. Sleep. 1999;22 Suppl 2:S366–S372.
67. Spoormaker VI, Montgomery P. Disturbed sleep in post-traumatic stress 98. Ancoli-Israel S, Ayalon L, Salzman C. Sleep in the elderly: normal variations
disorder: secondary symptom or core feature? Sleep Med Rev. 2008;12:169–184. and common sleep disorders. Harv Rev Psychiatry. 2008;16:279–286.
68. Lamarche LJ, De Koninck J. Sleep disturbance in adults with posttraumatic 99. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered
stress disorder: a review. J Clin Psychiatry. 2007;68:1257–1270. breathing among middle-aged adults. N Engl J Med. 1993;328:1230–1235.
69. Raboni MR, Tufik S, Suchecki D. Treatment of PTSD by eye movement 100. Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in
desensitization reprocessing (EMDR) improves sleep quality, quality of life, and community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med.
perception of stress. Ann N Y Acad Sci. 2006;1071:508–513. 2002;162:893–900.
70. Krakow B, Melendrez D, Pedersen B, et al. Complex insomnia: insomnia and 101. Norman D, Loredo JS. Obstructive sleep apnea in older adults. Clin Geriatr
sleep-disordered breathing in a consecutive series of crime victims with Med. 2008;24:151–165, ix.
nightmares and PTSD. Biol Psychiatry. 2001;49:948–953. 102. Ancoli-Israel S, Klauber MR, Butters N, et al. Dementia in institutionalized
71. Krakow B, Lowry C, Germain A, et al. A retrospective study on improvements elderly: relation to sleep apnea. J Am Geriatr Soc. 1991;39:258–263.
in nightmares and post-traumatic stress disorder following treatment for 103. Groth M. Sleep apnea in the elderly. Clin Geriatr Med. 2005;21:701–712, vi.
co-morbid sleep-disordered breathing. J Psychosom Res. 2000;49:291–298. 104. Aloia MS, Ilniczky N, Di Dio P, et al. Neuropsychological changes and
72. Krakow B, Melendrez D, Warner TD, et al. Signs and symptoms of treatment compliance in older adults with sleep apnea. J Psychosom Res.
sleep-disordered breathing in trauma survivors: a matched comparison with 2003;54:71–76.
classic sleep apnea patients. J Nerv Ment Dis. 2006;194:433–439. 105. Haas DC, Foster GL, Nieto FJ, et al. Age-dependent associations between
73. Germain A, Buysse DJ, Nofzinger E. Sleep-specific mechanisms underlying sleep-disordered breathing and hypertension: importance of discriminating
posttraumatic stress disorder: integrative review and neurobiological hypotheses. between systolic/diastolic hypertension and isolated systolic hypertension in the
Sleep Med Rev. 2008;12:185–195. Sleep Heart Health Study. Circulation. 2005;111:614–621.
74. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled 106. Pack AI, Maislin G. Who should get treated for sleep apnea? Ann Intern Med.
study of prazosin for trauma nightmares and sleep disturbance in combat 2001;134:1065–1067.
veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61:928–934. 107. Ayalon L, Ancoli-Israel S, Stepnowsky C, et al. Adherence to continuous
75. Miller LJ. Prazosin for the treatment of posttraumatic stress disorder sleep positive airway pressure treatment in patients with Alzheimer’s disease and
disturbances. Pharmacotherapy. 2008;28:656–666. obstructive sleep apnea. Am J Geriatr Psychiatry. 2006;14:176–180.
76. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in 108. Hornyak M, Trenkwalder C. Restless legs syndrome and periodic limb
patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. movement disorder in the elderly. J Psychosom Res. 2004;56:543–548.
2001;34:128–131. 109. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased
sexual desire with dopaminergic medications in restless legs syndrome. Clin
77. Lewis JD. Mirtazapine for PTSD nightmares. Am J Psychiatry.
Neuropharmacol. 2007;30:249–255.
2002;159:1948–1949.
110. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour
78. States JH, St Dennis CD. Chronic sleep disruption and the reexperiencing cluster
disorder: demographic, clinical and laboratory findings in 93 cases. Brain.
of posttraumatic stress disorder symptoms are improved by olanzapine: brief
2000;123(Pt 2):331–339.
review of the literature and a case-based series. Prim Care Companion J Clin
111. Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of ‘idiopathic’ REM
Psychiatry. 2003;5:74–79.
sleep behaviour disorder and olfactory dysfunction as possible indicator for
79. David D, De Faria L, Mellman TA. Adjunctive risperidone treatment and sleep
alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.
symptoms in combat veterans with chronic PTSD. Depress Anxiety.
Brain. 2005;128:126–137.
2006;23:489–491.
112. Britton TC, Chaudhuri KR. REM-sleep behavior disorder and the risk of
80. Robert S, Hamner MB, Kose S, et al. Quetiapine improves sleep disturbances in
developing Parkinson disease or dementia. Neurology. 2009;72(15):1294–1295.
combat veterans with PTSD: sleep data from a prospective, open-label study.
113. Postuma RB, Gagnon JF, Vendette M, . Quantifying the risk of
J Clin Psychopharmacol. 2005;25:387–388.
neurodegenerative disease in idiopathic REM sleep behavior disorder.
81. Lambert MT. Aripiprazole in the management of post-traumatic stress disorder Neurology. 2009;72(15):1296–1300.
symptoms in returning Global War on Terrorism veterans. Int Clin
114. Louden MB, Morehead MA, Schmidt HS. Activation by selegiline (Eldepryle)
Psychopharmacol. 2006;21:185–187.
of REM sleep behavior disorder in parkinsonism. W V Med J. 1995;91(3):101.
82. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive 115. Winkelman JW, James L. Serotonergic antidepressants are associated with
therapy in chronic civilian posttraumatic stress disorder: a preliminary report. REM sleep without atonia. Sleep. 2004;27:317–321.
J Clin Psychiatry. 2002;63:15–20. 116. Onofrj M, Luciano AL, Thomas A, et al. Mirtazapine induces REM sleep
83. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, behavior disorder (RBD) in parkinsonism. Neurology. 2003;60:113–115.
clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13:141–146. 117. Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM
84. Fraser GA. The use of a synthetic cannabinoid in the management of sleep behavior disorder. Neurology. 2006;67:742–747.
treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS 118. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep
Neurosci Ther. 2009;15:84–88. behavior disorder in neurologic disorders: results in 14 patients. Sleep Med.
85. Sageman S, Brown RP. 3-acetyl-7-oxo-dehydroepiandrosterone for healing 2003;4:281–284.
treatment-resistant posttraumatic stress disorder in women: 5 case reports. J Clin 119. Schnelle JF, Cruise PA, Alessi CA, et al. Sleep hygiene in physically dependent
Psychiatry. 2006;67:493–496. nursing home residents: behavioral and environmental intervention
86. Berger W, Mendlowicz MV, Marques-Portella C, et al. Pharmacologic implications. Sleep. 1998;21:515–523.
alternatives to antidepressants in posttraumatic stress disorder: a systematic 120. Yesavage JA, Friedman L, Ancoli-Israel S, et al. Development of diagnostic
review. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:169–180. criteria for defining sleep disturbance in Alzheimer’s disease. J Geriatr
87. Neylan TC, Metzler TJ, Schoenfeld FB, et al. Fluvoxamine and sleep Psychiatry Neurol. 2003;16:131–139.
disturbances in posttraumatic stress disorder. J Trauma Stress. 2001;14:461–467. 121. Mishima K, Tozawa T, Satoh K, et al. Melatonin secretion rhythm disorders in
88. Mellman TA, Bustamante V, David D, et al. Hypnotic medication in the patients with senile dementia of Alzheimer’s type with disturbed sleep-waking.
aftermath of trauma. J Clin Psychiatry. 2002;63:1183–1184. Biol Psychiatry. 1999;45:417–421.
89. Wills L, Garcia J. Parasomnias: epidemiology and management. CNS Drugs. 122. Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly
2002;16:803–810. people by controlled-release melatonin. Lancet. 1995;346:541–544.
90. Espiritu JR. Aging-related sleep changes. Clin Geriatr Med. 2008;24:1–14, v. 123. Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or
91. Ancoli-Israel S. Sleep problems in older adults: putting myths to bed. Geriatrics. agitation in double-blind randomized placebo-controlled trial of
1997;52:20–30. institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry.
92. Barbar SI, Enright PL, Boyle P, et al. Sleep disturbances and their correlates in 2009;17:166–169.
elderly Japanese American men residing in Hawaii. J Gerontol A Biol Sci Med 124. Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for
Sci. 2000;55:M406–M411. the assessment and management of sleep disorders in older persons. J Am
93. Crenshaw MC, Edinger JD. Slow-wave sleep and waking cognitive performance Geriatr Soc. 2009;57:761–789.
among older adults with and without insomnia complaints. Physiol Behav. 125. Alessi CA, Schnelle JF. Approach to sleep disorders in the nursing home
1999;66:485–492. setting. REVIEW ARTICLE. Sleep Med Rev. 2000;4:45–56.

The Canadian Journal of Psychiatry, Vol 55, No 7, July 2010 W 411


In Review

126. Ancoli-Israel S, Gehrman P, Martin JL, et al. Increased light exposure 140. Howe RC, Hegge FW, Phillips JL. Acute heroin abstinence in man: II.
consolidates sleep and strengthens circadian rhythms in severe Alzheimer’s Alterations in rapid eye movement (REM) sleep. Drug Alcohol Depend.
disease patients. Behav Sleep Med. 2003;1:22–36. 1980;6:149–161.
127. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies 141. Howe RC, Hegge FW, Phillips JL. Acute heroin abstinence in man: I. Changes
for late-life insomnia: a randomized controlled trial. JAMA. 1999;281:991–999. in behavior and sleep. Drug Alcohol Depend. 1980;5:341–356.
128. Pressman MR. Factors that predispose, prime and precipitate NREM 142. Roehrs T, Hyde M, Blaisdell B, et al. Sleep loss and REM sleep loss are
parasomnias in adults: clinical and forensic implications. Sleep Med Rev. hyperalgesic. Sleep. 2006;29:145–151.
2007;11:5–30; discussion 1–3. 143. Dimsdale JE, Norman D, DeJardin D, et al. The effect of opioids on sleep
architecture. J Clin Sleep Med. 2007;3:33–36.
129. Costa e Silva JA, Chase M, Sartorius N, et al. Special report from a symposium
held by the World Health Organization and the World Federation of Sleep 144. Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable
Research Societies: an overview of insomnias and related methadone maintenance treatment patients. Chest. 2005;128:1348–1356.
disorders—recognition, epidemiology, and rational management. Sleep. 145. Webster LR, Choi Y, Desai H, et al. Sleep-disordered breathing and chronic
1996;19:412–416. opioid therapy. Pain Med. 2008;9:425–432.
146. Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor
130. Stein MD, Friedmann PD. Disturbed sleep and its relationship to alcohol use.
for the development of central sleep apnea and ataxic breathing. J Clin Sleep
Subst Abus. 2005;26:1–13.
Med. 2007;3:455–461.
131. Drummond SP, Gillin JC, Smith TL, et al. The sleep of abstinent pure primary 147. Nicholson AN, Turner C, Stone BM, et al. Effect of
alcoholic patients: natural course and relationship to relapse. Alcohol Clin Exp Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and
Res. 1998;22:1796–1802. early-morning behavior in young adults. J Clin Psychopharmacol.
132. Brower KJ, Aldrich MS, Robinson EA, et al. Insomnia, self-medication, and 2004;24:305–313.
relapse to alcoholism. Am J Psychiatry. 2001;158:399–404. 148. Murillo-Rodriguez E. The role of the CB1 receptor in the regulation of sleep.
133. Clark CP, Gillin JC, Golshan S, et al. Increased REM sleep density at admission Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1420–1427.
predicts relapse by three months in primary alcoholics with a lifetime diagnosis 149. Schierenbeck T, Riemann D, Berger M, et al. Effect of illicit recreational drugs
of secondary depression. Biol Psychiatry. 1998;43:601–607. upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12:381–389.
134. Le Bon O, Murphy JR, Staner L, et al. Double-blind, placebo-controlled study of 150. Budney AJ, Hughes JR, Moore BA, et al. Review of the validity and
the efficacy of trazodone in alcohol post-withdrawal syndrome: significance of cannabis withdrawal syndrome. Am J Psychiatry.
polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2004;161:1967–1977.
2003;23:377–383.
135. Malcolm R, Myrick H, Roberts J, et al. The differential effects of medication on
mood, sleep disturbance, and work ability in outpatient alcohol detoxification.
Am J Addict. 2002;11:141–150.
Manuscript received, revised, and accepted October 2009.
1
Assistant Professor, Faculty of Medicine, University of Ottawa,
136. Staner L, Boeijinga P, Danel T, et al. Effects of acamprosate on sleep during
alcohol withdrawal: a double-blind placebo-controlled polysomnographic study Department of Psychiatry and Psychology, Ottawa, Ontario.
2
in alcohol-dependent subjects. Alcohol Clin Exp Res. 2006;30:1492–1499. Sleep Specialist, Sleep Disorders Clinic, Royal Ottawa Mental Health
137. Malcolm R, Myrick LH, Veatch LM, et al. Self-reported sleep, sleepiness, and Centre, Ottawa, Ontario.
3
repeated alcohol withdrawals: a randomized, double blind, controlled Medical Director, Sleep Disorders Clinic, University of Ottawa Institute
comparison of lorazepam vs gabapentin. J Clin Sleep Med. 2007;3:24–32. of Mental Health Research and Royal Ottawa Mental Health Centre,
138. Andersen ML, Poyares D, Alves RS, et al. Sexsomnia: abnormal sexual behavior Ottawa, Ontario.
during sleep. Brain Res Rev. 2007;56:271–282. Address for correspondence: Dr EK Lee, Sleep Disorders Clinic, Royal
139. Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered Ottawa Mental Health Centre, 1145 Carling Avenue, Ottawa, ON
breathing. Sleep Med Rev. 2007;11:35–46. K1Z 7K4; elliott.lee@rohcg.on.ca

Résumé : Le sommeil dans les troubles psychiatriques : où en


sommes-nous?
Bien que la fonction précise du sommeil soit inconnue, des décennies de recherche suggèrent
fortement que le sommeil a un rôle essentiel dans la restauration du système nerveux central (SNC),
la consolidation de la mémoire, et la régulation de l’affect. Le sommeil à onde lente (SOL) et le
sommeil paradoxal (SP) présentent un intérêt significatif pour les psychiatres; le SOL en raison de
son rôle présumé dans la récupération d’énergie et la fonction cognitive du SNC, et le SP à cause de
sa participation suggérée à la mémoire, à la régulation de l’humeur, et à une possible adaptation
émotionnelle. Avec l’arrivée du polysomnograph, les chercheurs commencent maintenant à
comprendre certaines conséquences du sommeil perturbé et de la privation de sommeil dans les
troubles psychiatriques. La même neurochimie qui contrôle le cycle sommeil-éveil est également
impliquée dans la pathophysiologie de nombreux troubles psychiatriques. Il n’est donc pas étonnant
que plusieurs troubles psychiatriques aient des symptômes de sommeil dominants. Cette étude
résumera l’architecture normale du sommeil, puis examinera les anomalies du sommeil et les
troubles du sommeil comorbides observés dans la schizophrénie, ainsi que dans les troubles
anxieux, cognitifs, et liés à l’abus de substances.

412 W La Revue canadienne de psychiatrie, vol 55, no 7, juillet 2010